This Month in Gastroenterology

Percentage of patients in remission versus recurrence 1 year after intestinal resection for Crohn's disease by random assignment to infliximab or placebo.

Outcomes of therapy and occurrence of viral resistance during treatment with lamivudine and telbivudine in chronic hepatitis B patients who are HBeAG positive or HBeAG negative.

Hepatitis C viral responses to the combination therapy of peginterferon alfa-2a and ribavirin. Intention-to-treat (ITT): analysis of patients receiving ≥1 dose of study treatment, including withdrawals; withdrawn cases without HCV RNA testing at 24 weeks posttreatment are counted as treatment failure. Per protocol (PP): analysis of patients completing ≥12 weeks of treatment. B+C, HBsAg-positive patients with chronic hepatitis C; C, HBsAg-negative patients with chronic hepatitis C; VR, virologic response (HCV RNA clearance at the end of treatment); SVR, sustained virologic response (HCV RNA clearance at 24 weeks posttreatment).

ILZ-TG (transgenic) mice are less susceptible than WT mice to DNBS-induced colitis. Four and 7 days after DNBS administration, mice were killed and body weight (A) and macroscopic damage score (B) evaluated. Bars are the means ± SE of 10 mice for each group. *P < .01 DNBS versus vehicle; ^oP < .01 DNBS-treated GILZ-TG versus DNBS-treated WT.